Evogene Ltd. Statistics
Share Statistics
Evogene Ltd. has 5.37M shares outstanding. The number of shares has increased by -89.99% in one year.
Shares Outstanding | 5.37M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | -90% |
Owned by Institutions (%) | n/a |
Shares Floating | 5.28M |
Failed to Deliver (FTD) Shares | 701 |
FTD / Avg. Volume | 0.24% |
Short Selling Information
The latest short interest is 22.35K, so 0.42% of the outstanding shares have been sold short.
Short Interest | 22.35K |
Short % of Shares Out | 0.42% |
Short % of Float | 0.42% |
Short Ratio (days to cover) | 0.04 |
Valuation Ratios
The PE ratio is -15.78 and the forward PE ratio is -0.57.
PE Ratio | -15.78 |
Forward PE | -0.57 |
PS Ratio | 66.81 |
Forward PS | 0.4 |
PB Ratio | 31.26 |
P/FCF Ratio | -16.85 |
PEG Ratio | n/a |
Enterprise Valuation
Evogene Ltd. has an Enterprise Value (EV) of 18.74M.
EV / Earnings | -0.78 |
EV / Sales | 3.32 |
EV / EBITDA | -0.81 |
EV / EBIT | -0.71 |
EV / FCF | -0.84 |
Financial Position
The company has a current ratio of 4.96, with a Debt / Equity ratio of 0.86.
Current Ratio | 4.96 |
Quick Ratio | 4.95 |
Debt / Equity | 0.86 |
Total Debt / Capitalization | 46.24 |
Cash Flow / Debt | -2.08 |
Interest Coverage | -230.5 |
Financial Efficiency
Return on equity (ROE) is -1.98% and return on capital (ROIC) is -65.58%.
Return on Equity (ROE) | -1.98% |
Return on Assets (ROA) | -0.47% |
Return on Capital (ROIC) | -65.58% |
Revenue Per Employee | 39.72K |
Profits Per Employee | -168.16K |
Employee Count | 142 |
Asset Turnover | 0.11 |
Inventory Turnover | 22.26 |
Taxes
Income Tax | -33.00K |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -80.73% in the last 52 weeks. The beta is 1.08, so Evogene Ltd.'s price volatility has been higher than the market average.
Beta | 1.08 |
52-Week Price Change | -80.73% |
50-Day Moving Average | 2.05 |
200-Day Moving Average | 5.01 |
Relative Strength Index (RSI) | 28.42 |
Average Volume (20 Days) | 286.47K |
Income Statement
In the last 12 months, Evogene Ltd. had revenue of $5.64M and earned -$23.88M in profits. Earnings per share was $-5.23.
Revenue | 5.64M |
Gross Profit | 1.40M |
Operating Income | -26.39M |
Net Income | -23.88M |
EBITDA | -23.20M |
EBIT | -26.39M |
Earnings Per Share (EPS) | -5.23 |
Balance Sheet
The company has $20.77M in cash and $11.51M in debt, giving a net cash position of $9.27M.
Cash & Cash Equivalents | 20.77M |
Total Debt | 11.51M |
Net Cash | 9.27M |
Retained Earnings | -257.59M |
Total Assets | 40.11M |
Working Capital | 2.07M |
Cash Flow
In the last 12 months, operating cash flow was -$21.58M and capital expenditures -$785.00K, giving a free cash flow of -$22.36M.
Operating Cash Flow | -21.58M |
Capital Expenditures | -785.00K |
Free Cash Flow | -22.36M |
FCF Per Share | -0.49 |
Margins
Gross margin is 70%, with operating and profit margins of -470% and -423.39%.
Gross Margin | 70% |
Operating Margin | -470% |
Pretax Margin | -460.76% |
Profit Margin | -423.39% |
EBITDA Margin | -411.42% |
EBIT Margin | -467.93% |
FCF Margin | -396.49% |
Dividends & Yields
EVGN does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -396.21% |
FCF Yield | -315.96% |
Analyst Forecast
The average price target for EVGN is $12, which is 809.1% higher than the current price. The consensus rating is "Buy".
Price Target | $12 |
Price Target Difference | 809.1% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Stock Splits
The last stock split was on Jul 25, 2024. It was a backward split with a ratio of 1:10.
Last Split Date | Jul 25, 2024 |
Split Type | backward |
Split Ratio | 1:10 |
Scores
Altman Z-Score | -11.02 |
Piotroski F-Score | 3 |